Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Mol Pharmacol. 2013 May;83(5):939-48. doi: 10.1124/mol.112.084483. Epub 2013 Feb 12.
The role of α₁-adrenergic receptors (ARs) in the regulation of cardiac hypertrophy is still unclear, because transgenic mice demonstrated hypertrophy or the lack of it despite high receptor overexpression. To further address the role of the α₁-ARs in cardiac hypertrophy, we analyzed unique transgenic mice that overexpress constitutively active mutation (CAM) α₁A-ARs or CAM α₁B-ARs under the regulation of large fragments of their native promoters. These constitutively active receptors are expressed in all tissues that endogenously express their wild-type counterparts as opposed to only myocyte-targeted transgenic mice. In this study, we discovered that CAM α₁A-AR mice in vivo have cardiac hypertrophy independent of changes in blood pressure, corroborating earlier studies, but in contrast to myocyte-targeted α₁A-AR mice. We also found cardiac hypertrophy in CAM α₁B-AR mice, in agreement with previous studies, but hypertrophy only developed in older mice. We also discovered unique α₁-AR-mediated hypertrophic signaling that was AR subtype-specific with CAM α₁A-AR mice secreting atrial naturietic factor and interleukin-6 (IL-6), whereas CAM α₁B-AR mice expressed activated nuclear factor-κB (NF-κB). These particular hypertrophic signals were blocked when the other AR subtype was coactivated. We also discovered that crossbreeding the two CAM models (double CAM α₁A/B-AR) inhibited the development of hypertrophy and was reversible with single receptor activation, suggesting that coactivation of the receptors can lead to novel antagonistic signal transduction. This was confirmed by demonstrating antagonistic signals that were even lower than normal controls in the double CAM α₁A/B-AR mice for p38, NF-κB, and the IL-6/glycoprotein 130/signal transducer and activator of transcription 3 pathway. Because α₁A/B double knockout mice fail to develop hypertrophy in response to IL-6, our results suggest that IL-6 is a major mediator of α₁A-AR cardiac hypertrophy.
α₁-肾上腺素能受体(ARs)在心脏肥大中的作用尚不清楚,因为转基因小鼠尽管受体过度表达,但表现出肥大或缺乏。为了进一步研究 α₁-AR 在心脏肥大中的作用,我们分析了在其天然启动子的大片段调控下过表达组成型激活突变(CAM)α₁A-AR 或 CAM α₁B-AR 的独特转基因小鼠。这些组成型激活的受体在所有表达其野生型对应物的组织中表达,而不是仅在心肌靶向转基因小鼠中表达。在这项研究中,我们发现体内 CAM α₁A-AR 小鼠有心脏肥大而血压没有变化,这与早期的研究一致,但与心肌靶向的 α₁A-AR 小鼠相反。我们还发现 CAM α₁B-AR 小鼠有心脏肥大,这与以前的研究一致,但肥大仅发生在老年小鼠中。我们还发现了独特的 α₁-AR 介导的肥大信号,该信号具有 AR 亚型特异性,CAM α₁A-AR 小鼠分泌心钠素和白细胞介素-6(IL-6),而 CAM α₁B-AR 小鼠表达激活的核因子-κB(NF-κB)。当其他 AR 亚型共同激活时,这些特定的肥大信号被阻断。我们还发现,两种 CAM 模型(双 CAM α₁A/B-AR)的杂交抑制了肥大的发展,并且可以通过单一受体激活逆转,这表明受体的共同激活可以导致新的拮抗信号转导。通过在双 CAM α₁A/B-AR 小鼠中证明甚至低于正常对照的拮抗信号证实了这一点,这些信号对于 p38、NF-κB 和 IL-6/糖蛋白 130/信号转导和转录激活因子 3 途径来说是拮抗的。由于 α₁A/B 双敲除小鼠对 IL-6 没有反应而不会发生肥大,我们的结果表明 IL-6 是 α₁A-AR 心脏肥大的主要介质。